After rebounding in 2021 following the challenges caused by the COVID-19 pandemic, M&A dealmaking took a surprising turn in the first half of 2022 with a significant decline in activity, both in terms of deal volume and value, amid challenging market conditions and escalating geopolitical tensions. This reduced appetite for M&A continued into Q3 2022 as ongoing uncertainties led risk-averse pharmaceutical companies to enter smaller scale, asset-driven acquisitions opposed to big-ticket transformational buyouts.

Please fill in your details on the left, to download the article